Viridian Therapeutics, Inc. $VRDN Shares Bought by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 27.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 90,019 shares of the company’s stock after purchasing an additional 19,466 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Viridian Therapeutics were worth $1,853,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in VRDN. KBC Group NV acquired a new position in Viridian Therapeutics during the 1st quarter valued at approximately $34,000. Integrated Wealth Concepts LLC bought a new position in Viridian Therapeutics during the 2nd quarter worth $33,000. State of Wyoming acquired a new stake in Viridian Therapeutics in the second quarter worth $43,000. Fulcrum Asset Management LLP acquired a new stake in Viridian Therapeutics in the third quarter worth $97,000. Finally, AlphaCentric Advisors LLC bought a new stake in Viridian Therapeutics in the third quarter valued at $216,000.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VRDN. Wall Street Zen raised shares of Viridian Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 7th. HC Wainwright upped their price target on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Needham & Company LLC increased their price objective on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Wedbush lifted their price objective on shares of Viridian Therapeutics from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Finally, Truist Financial boosted their target price on shares of Viridian Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Insider Activity

In other news, insider Jennifer Tousignant sold 14,212 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $31.25 on Thursday. Viridian Therapeutics, Inc. has a 12-month low of $13.18 and a 12-month high of $34.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 14.46 and a quick ratio of 14.46. The firm has a market capitalization of $3.55 billion, a price-to-earnings ratio of -8.14 and a beta of 1.07. The business has a 50 day simple moving average of $22.44 and a 200 day simple moving average of $21.78.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 79.67% and a negative net margin of 1,620.79%. The firm had revenue of $25.75 million for the quarter, compared to the consensus estimate of $4.72 million. On average, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -3.64 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.